Surprisingly, our findings discovered that the ESCMe can downregulate the PI3K pathway in tumor cells but upregulate in somatic cells, thus playing a dual role in reversing the malignancy of the tumor as well as preventing the senescence of somatic cells both in vitro and in vivo. Here, PIK3CG is linked to neoplasm.